Considering a Few Small-Cap Biotech Plays

Biotech may be the most difficult sector in the market to invest in. The complications of coming up with a new product or compound, getting it through Phase I, II and III trials and all the way to federal approval is a long and arduous process. For every success, there are at least half dozen failures. Hedge funds that employ PHDs in biochemistry still have their share of clunkers. Biotech is built to drive investors crazy. For every dozen investments, expect three to four to fail, two to muddle along and be worth half what you put in two to three years down the road, two to show some minor progress and break even. Two will be substantial successes and become 2-4 baggers and if you are fortunate, one or two will produce a major discovery and/or be bought out that will make them five to 20 baggers or more.

That is why I prefer a shotgun approach to investing in this sector. The best way to invest in biotech is to spread your money around by accumulating small positions in at least a dozen firms. These companies should be focusing on interesting areas, are trading significantly below analysts' price targets, have strong and committed management and either have cash flow or enough cash on hand to get them through critical milestones. Here are a few small-cap biotech plays that meet these criteria and should be considered by aggressive investors....434 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.